NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
Key Highlights
- ➤Updated givastomig Phase 1b combination data will be presented at ESMO Congress 2026.
- ➤Givastomig is advancing toward registrational development in first-line metastatic gastroesophageal adenocarcinoma.
- ➤Global randomized Phase 2 study NCT07432295 is evaluating givastomig after positive Phase 1b topline results.
- ➤FDA granted Fast Track Designation for givastomig with nivolumab and chemotherapy.
Expert Statements
Phillip Dennis, Chief Medical Officer of NovaBridge Biosciences
“Patients with metastatic gastroesophageal adenocarcinoma continue to need more effective treatment options, particularly those whose tumors express lower levels of CLDN18.2”
Phillip Dennis, Chief Medical Officer of NovaBridge Biosciences
“Givastomig is designed to amplify T-cell activity where CLDN18.2 is expressed.”
Phillip Dennis, Chief Medical Officer of NovaBridge Biosciences
“The data we plan to share at ESMO will provide a more mature view of the safety, efficacy and durability observed to date in combination with nivolumab and chemotherapy.”
Phillip Dennis, Chief Medical Officer of NovaBridge Biosciences
“These findings further strengthen our confidence in the program as we advance toward registrational development in first-line metastatic gastroesophageal adenocarcinoma.”
ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in participants with previously untreated, HER2-negative, CLDN18.2-positive, and PD-L1-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (GEA), will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. ESMO Congress 2026 is scheduled to take place October 23-27, 2026, in Madrid, Spain.
“Patients with metastatic gastroesophageal adenocarcinoma continue to need more effective treatment options, particularly those whose tumors express lower levels of CLDN18.2,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Givastomig is designed to amplify T-cell activity where CLDN18.2 is expressed. The data we plan to share at ESMO will provide a more mature view of the safety, efficacy and durability observed to date in combination with nivolumab and chemotherapy. These findings further strengthen our confidence in the program as we advance toward registrational development in first-line metastatic gastroesophageal adenocarcinoma.”
Get started
Create a free account to read the full story.